Peptide Briefs

Home / Peptide Profiles / CJC-1295: What the Research Looks At

CJC-1295: What the Research Looks At

Updated 2026-09-03

An education-first look at CJC-1295: what it is, how the DAC and non-DAC variants differ, and its regulatory status. Not medical advice.

This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.

What it is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate the pituitary gland's own growth hormone release rather than supplying growth hormone directly. It is sold in two commonly discussed forms: CJC-1295 with Drug Affinity Complex (DAC), which is chemically modified to bind to a blood protein and extend its active window, and CJC-1295 without DAC, sometimes labeled Mod GRF 1-29, which more closely resembles the original GHRH fragment and is described in the literature as shorter-acting. Neither form is approved by the FDA for any human use, and neither is a dietary supplement ingredient. Products sold under either name online are not standardized or independently verified for purity outside a lab setting.

How it is studied

Early human and animal studies of GHRH analogs related to CJC-1295 date back to the 2000s, examining growth hormone and IGF-1 response after administration in small study groups. A search of PubMed and ClinicalTrials.gov shows this early research has not been followed by a large, modern, placebo-controlled trial program comparable to what supported the approved GHRH analog tesamorelin for its specific indication. Much of the current interest in CJC-1295 online traces back to that older, limited literature and to manufacturer or community-sourced material rather than a broad, independently replicated modern evidence base. Researchers publishing on GHRH analogs generally describe this category's human evidence as preliminary.

What the research looks at

Published research connected to CJC-1295 and related GHRH analogs has explored growth hormone and IGF-1 response patterns, the pharmacokinetic effect of the DAC modification on how long a compound remains active, and some animal-model work on body composition. Researchers frame these as areas of investigation, and the DAC modification's extended activity window is a pharmacokinetic property studied in early research rather than a demonstrated clinical outcome for a general user population.

Regulatory status

Neither CJC-1295 with DAC nor without DAC has been approved by the FDA for any indication. As compounded or research-grade substances, both sit under the general 503A and 503B compounding framework applicable to other unapproved peptides, and FDA compounding policy toward substances in this category has changed more than once in recent years (see /regulation/fda-category-2-list-explained/ and /regulation/503a-vs-503b-compounding-explained/). Readers should check the current /regulation/fda-compounding-rulings-2026-update/ page rather than assume a fixed legal status. International status varies; see the relevant /regulation/ country pages before assuming the same rules apply outside the United States.

Safety signals reported

Independent, controlled human safety data on CJC-1295 is limited, and this is particularly true for the DAC variant's longer exposure window, which has not been studied in a large controlled trial. Reports circulating online are largely anecdotal. Sourcing outside a licensed pharmacy channel is itself a safety consideration, since purity, sterility, and labeled content are not independently confirmed for products sold this way. Growth hormone-releasing peptides as a class carry theoretical considerations around blood sugar regulation and fluid balance that a licensed provider is positioned to evaluate for an individual's health history. This is not medical advice. Discuss any decision about a research or compounded substance with a licensed healthcare provider first.

Questions to ask a clinician

FAQ

Is CJC-1295 approved by the FDA? No. CJC-1295 has not been approved by the FDA for any human use, in either of its commonly sold forms, and it is not a dietary supplement ingredient.

What is the difference between CJC-1295 with DAC and without DAC? CJC-1295 with Drug Affinity Complex (DAC) is chemically modified to extend how long it remains active, while the version without DAC, sometimes labeled Mod GRF 1-29, is closer to the original GHRH fragment and is described as shorter-acting. Products sold under either name are not standardized or independently verified for purity.

Has CJC-1295 been tested in humans? Some early-phase human research exists, mostly from studies conducted more than a decade ago in limited populations, alongside animal and cell-based research. Large, modern, placebo-controlled trials of CJC-1295 have not been published as of this update.

Is CJC-1295 legal to buy in the United States? CJC-1295 is not approved by the FDA and is not permitted as a dietary supplement ingredient sold at retail. Its status under 503A and 503B compounding rules has been subject to periodic review, so readers should check current FDA guidance rather than assume a fixed status.

Sources

Disclaimer

This content is for general education only and is not medical advice, diagnosis, or treatment. Peptide Briefs does not sell peptides and does not recommend any specific product, dose, or protocol. These statements have not been evaluated by the Food and Drug Administration. Always talk with a licensed healthcare provider before starting, stopping, or changing any therapy.

Recommended stack

Creatine Surge
Download ApexZen Coach